Eisai and Biogen Inc. Announce U.S. FDA Grants Breakthrough Therapy Designation for Lecanemab (BAN2401), an Anti-Amyloid Beta Protofibril Antibody for the Treatment of Alzheimer ' s Disease

TOKYO and CAMBRIDGE, Mass, -- June 23, 2021 -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito,“Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos,“Biogen”)...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials